Patients with gMG face significant challenges in daily living, fatigue, and work ability, despite treatment adherence. A 2024 survey highlights poor quality of life and significant impairment in ...

Rystiggo (rozanolixizumab) has been given the green light by the FDA for both anti-AChR and anti-MuSK antibody-positive gMG based on the results of the MycarinG study, which showed that treatment ...

Inebilizumab showed significant efficacy in improving MG-ADL and QMG scores in gMG patients compared to placebo over 26 weeks. The trial included 238 patients, with 80% AChR+ and 20% MuSK+ ...

The EMA’s human medicines committee issued a positive opinion on Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of adult gMG patients who are anti-acetylcholine ...